Androgen deprivation therapy
Aliases
ADT, Chemotherapy-Hormones/Steroids, endocrine therapy, Endocrine Therapy, Hormonal Therapy (3 other aliases)
19 clinical trials
33 products
17 abstracts
12 indications
5 targets
Indication
Prostate CancerIndication
Neoadjuvant TherapyIndication
Castration-ResistantIndication
Prostate NeoplasmsIndication
Prostate Cancer, Stage III AJCC v8Indication
Prostate Cancer Stage IIIB AJCC v8Indication
Prostate AdenocarcinomaIndication
Metastatic CancerIndication
Oligometastatic CancerIndication
Ductal Carcinoma In SituTarget
androgen receptorTarget
CYP17,20 lyaseTarget
androgen receptorsTarget
testosteroneIndication
AntiandrogensIndication
Prostate cancerClinical trial
Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate CancerStatus: Recruiting, Estimated PCD: 2026-04-30
Abstract
Debunking the frailty-sarcopenia-ADT axis in metastatic prostate cancer with multicomponent exercise: The FIERCE trial.Org: Roslindale, MA, Massachusetts Institute of Technology,
Clinical trial
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST TrialStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Combination of Darolutamide and Stereotactic Body Radiation Therapy in Patients With Castration Resistant Prostate Cancer and Oligometastases on Functional ImagingStatus: Not yet recruiting, Estimated PCD: 2024-07-01
Clinical trial
Pilot Study to Identify Radiogenomic Biomarkers to Predict Early Treatment Response to Androgen Deprivation Therapy and Radiation Therapy in High Risk Prostate CancerStatus: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
A Randomized Phase II Study of ADT + Abiraterone Versus ADT + Docetaxel + Abiraterone in Patients With Low Volume Metastatic Hormone Sensitive Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-05-03
Clinical trial
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in de Novo Metastatic to Lymph Nodes Prostate CancerStatus: Not yet recruiting, Estimated PCD: 2026-12-31
Clinical trial
Strength, Aging, and Memory in Prostate Cancer: A Prospective Study of the Effects of Androgen Deprivation on Neurocognition and FrailtyStatus: Completed, Estimated PCD: 2023-04-11
Clinical trial
A Phase I Trial of Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy RadiotherapyStatus: Active (not recruiting), Estimated PCD: 2023-12-29
Clinical trial
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapyStatus: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for Adjuvant or Salvage Treatment for Rising PSA After Radical Prostatectomy (EXCALIBUR)Status: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
Weekly ModraDoc/r in Combination With Hormonal Treatment and High-dose Intensity-modulated Radiation Therapy in Patients With High-risk Early Stage Prostate CancerStatus: Terminated, Estimated PCD: 2022-02-01
Clinical trial
A Double-blind Randomised Phase III Trial Evaluating the Efficacy of ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability and Not Elected for Docetaxel or Androgen Receptor Targeted AgentsStatus: Recruiting, Estimated PCD: 2028-03-01
Clinical trial
A Phase 2 Multicohort Study of Nivolumab in Combination With Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients With DNA Damage Repair Defects or Inflamed TumorsStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)Status: Active (not recruiting), Estimated PCD: 2025-07-23
Clinical trial
PEACE V: A Randomized Phase II Trial for the Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases (STORM)Status: Active (not recruiting), Estimated PCD: 2023-04-30
Clinical trial
Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)Status: Active (not recruiting), Estimated PCD: 2027-11-01
Clinical trial
STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled TrialStatus: Active (not recruiting), Estimated PCD: 2026-03-01
Clinical trial
RAD 2003/XUAB2104: Randomized Phase II Trial of Flibanserin in Men Receiving Androgen Suppression for Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2025-03-01
Abstract
Association of Medicaid expansion with treatment receipt, delays in treatment initiation, and survival among young adult women with breast cancer.Org: American Cancer Society, Mayo Clinic, Emory University School of Medicine,
Abstract
The effect of maintenance hormone therapy on overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study.Org: Massachusetts General Hospital, Meigs Division of Gynecologic Oncology, Vincent Department of Obstetrics & Gynecology, University of Texas MD Anderson Cancer Center,
Abstract
Treatment outcomes in patients with discordant recurrence score and RSClin risk predictions.Org: University of Chicago, University of Chicago Medical Center, Chicago, IL, University of Chicago Department of Public Health Sciences, Center for Data Intensive Science at the University of Chicago, Department of Medicine, University of Chicago,
Abstract
Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA.Org: Guardant Health, Inc., Mayo Clinic Florida, Mayo Clinic, Emory University, Atlanta, GA, USA, Miami Cancer Institute - Baptist Health South Florida,
Abstract
Androgen-deprivation therapy and risk of dementia in patients with prostate cancer: Clinical outcomes from real-world data.Org: MetroHealth Medical Center, Case Western Reserve University School of Medicine, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Seidman Cancer Center, Johns Hopkins University - School of Medicine,
Abstract
Nutrition assessment reports in oncology clinical trials.Org: Department of Supportive Oncology, Levine Cancer Institute, Atrium Health Carolinas Medical Center, Department of Internal Medicine at Atrium Health Carolinas Medical Center, Department of Solid Tumor Oncology and Supportive Oncology,
Abstract
Crossing the US-Mexico border for cancer care: Which treatments are more sought-after?Org: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, University of North Carolina at Chapel Hill, Vanderbilt University Medical Center, ISSSTE CMN 20 De Noviembre, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico,
Abstract
An analysis of National Cancer Data Base: Male breast cancer and overall survival.Org: Creighton University Medical Center, Creighton University School of Medicine Phoenix Regional Campus, Department of Hematology Oncology, Kaiser Permanente, University of Nebraska Medical Center, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University,
Abstract
Impact of COVID-19 pandemic on the treatment of prostate cancer in the Brazilian Public Health System.Org: LACOG - Latin American Cooperative Oncology Group, University of California, San Diego (UCSD), University of California at San Diego, Univeristy of California San Diego, Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil,
Abstract
Early integration of exercise into breast cancer care: The MSK Healthy Living program.Org: Memorial Sloan Kettering Cancer Center,
Abstract
How did the COVID-19 pandemic affect the management of patients with cancer? What is the impact of anti-cancer medications on the immune response to the COVID-19 vaccinations?Org: Moncton Hospital, Dalhousie University, The Moncton Hospital,
Abstract
The impact of the COVID-19 pandemic on the diagnosis and treatment of breast cancer at a community hospital.Org: Gundersen Health System, La Crosse, WI, Gundersen Medical Center,
Abstract
Neoadjuvant therapy (NAT) in early breast cancer (EBC): Results from a prospective observational multicenter BRIDE study.Org: Oncologia Medica - IRCCS Ospedale Sacro Cuore Don Calabria, Negrar Di Valpolicella (VR), Italy, IRCCS Regina Elena National Cancer Institute, Division of Medical Oncology 1, Rome, Italy, Roma, Italy, Oncologia - Humanitas Gavazzeni, Bergamo, Italy, Oncologia - Azienda Sanitaria dell’Alto Adige, Bolzano, Italy,
Abstract
Change in quality of life of metastatic breast cancer patients seeking treatment at Komfo Anokye Teaching Hospital, Ghana.Org: Komfo Anokye Teaching Hospital, Kumasi, Ashanti Region, Ghana,
Product
Antiandrogen TherapyAbstract
Preventable emergency department visits and admissions for patients on chemotherapy including oral chemotherapy.Org: Beth Israel Deaconess Medical Center, Boston, MA,
Abstract
Navigating how to choose an oncologist as part of the cancer journey.Org: CVS Health, Lincoln, RI,
Product
Bicalutamide + ADTProduct
ADT + Docetaxel + NivolumabProduct
ADT + BicalutamideProduct
ADT + AxitinibProduct
neo-ARPI + ADTProduct
Docetaxel + Prostvac + ADTProduct
M9241 + Docetaxel + ADTProduct
Apalutamide + ADT (AAT)Product
SBRT + ADTProduct
Enzalutamide + ADTProduct
ADT+ARPIProduct
ADT + cemiplimab + docetaxelProduct
darolutamide, docetaxel, ADTProduct
Rezvilutamide + ADTProduct
RT + short-term ADTClinical trial
Neoadjuvant Degarelix +/- Apalutamide (ARN-509) Followed by Radical Prostatectomy for Intermediate and High-risk Prostate Cancer: a Randomized, Placebo-controlled TrialStatus: Active (not recruiting), Estimated PCD: 2021-07-01